BioCentury
ARTICLE | Clinical News

Aeroquin: Phase III data

January 14, 2013 8:00 AM UTC

The open-label, international Phase III 209 trial in 282 CF patients with P. aeruginosa infection showed that twice-daily 240 mg Aeroquin for the first 28 days of a 56-day cycle met the primary endpoi...